A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...
Clinical Trials Arena on MSN
Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials
Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results